carfilzomib / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

175 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carfilzomib / Generic mfg.
STORM, NCT02336815 / 2016-003094-18: Selinexor Treatment of Refractory Myeloma

Hourglass Sep 2023 - Sep 2023 : Presentation of data from STORM trial for r/r multiple myeloma at IMS 2023
Checkmark Data from STORM trial in combination with dexamethasone for multiple myeloma
Aug 2020 - Aug 2020: Data from STORM trial in combination with dexamethasone for multiple myeloma
Checkmark Data from STORM trial at ASH 2018
Dec 2018 - Dec 2018: Data from STORM trial at ASH 2018
More
Completed
2b
202
Europe, US
Selinexor, KPT-330, Dexamethasone
Karyopharm Therapeutics Inc
Multiple Myeloma
07/19
07/19
NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma

Checkmark P2 data
Jul 2012 - Jul 2012: P2 data
Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Checkmark P2 data at ASH
More
Completed
2
312
US, Canada
carfilzomib, PR-171, PR171, Kyprolis® (carfilzomib) for Injection
Amgen
Multiple Myeloma
11/10
10/12
2010-021111-17: A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

Not yet recruiting
2
53
Europe
Carfilzomib, PR-171, Tablet, Powder and solvent for solution for injection, ENDOXAN BAXTER*50CPR RIV 50MG, SOLDESAM
HOVON Foundation
newly diagnosed multiple myeloma patients
 
 
NCT01346787: Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients

Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Completed
2
58
Europe
CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
European Myeloma Network, Fondazione EMN Italy Onlus
Multiple Myeloma
10/12
05/23
NCT00721734: Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Checkmark P2 data-ASCO
May 2012 - May 2012: P2 data-ASCO
Checkmark P2 data at ASH
Nov 2011 - Nov 2011: P2 data at ASH
Completed
2
50
US
Carfilzomib, PR-171, Kyprolis®
Amgen
Multiple Myeloma, Renal Insufficiency
11/12
11/12
NCT00530816: Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

Checkmark P2 data-ASCO
May 2012 - May 2012: P2 data-ASCO
Checkmark P2 data in MM
May 2012 - May 2012: P2 data in MM
Checkmark P2 data at ASH
More
Completed
2
164
US, Canada
carfilzomib, PR-171, PR171, Kyprolis® (carfilzomib) for Injection
Amgen
Multiple Myeloma
01/13
07/13
NCT00461045: Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Completed
2
15
US
MRZ 0.5 mg/m^2, Marizomib, NPI-0052
Celgene
Multiple Myeloma
09/14
10/14
NCT01813227: A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

Completed
2
7
US
Carfilzomib, Kyprolis, Rituximab, Rituxan, Dexamethasone, Decadron
Hackensack Meridian Health, Onyx Therapeutics, Inc.
Waldenstrom Macroglobulinemia
09/14
10/18
CARAMEL 2, NCT01812720: Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant

Withdrawn
2
0
US
carfilzomib, Kyprolis, PR-171, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, laboratory biomarker analysis
Mayo Clinic, National Cancer Institute (NCI)
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
09/14
10/14
2014-000782-53: This protocol is a phase II randomized, multicenter study designed to assess the safety and the efficacy of different carfilzomib combinations in newly diagnosed MM patients eligible for autologous transplantation (ASCT). Questo protocollo è uno studio di fase II randomizzato, multicentrico, per valutare la sicurezza e l'efficacia di differenti combinazioni di Carfilzomib in pazienti con nuova diagnosi di mieloma multiplo (MM), eleggibili al trapianto autologo (ASCT)

Ongoing
2
477
Europe
Carfilzomib, REVLIMID 5mg, REVLIMID 10 mg, REVLIMID 25 mg, PR-171, Powder for solution for injection, Capsule, hard, REVLIMID, REVLIMID 10mg, REVLIMID 25 mg
Università degli Studi di Torino-Dipartimento di Biotecnologie Molecolari e Scienze della Salute, Onix Therapeutics, Inc., Celgene Pharmaceuticals
NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT Pazienti affetti da Mieloma Multiplo (MM) alla diagnosi, eleggibili al trapianto autologo, NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT Pazienti affetti da Mieloma Multiplo (MM) alla diagnosi, eleggibili al trapianto autologo, Diseases [C] - Cancer [C04]
 
 
2013-003265-34: Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib. Inductie en consolidatie behandeling met Pomalidomide gecombineerd met Carfilzomib en dexamethason, gevolgd door onderhoudsbehandeling met Pomalidomide of Pomalidomide en dexamethason voor patiënten met Multipel Myeloom in progressie na een eerstelijns behandeling met Lenalidomide en Bortezomib

Ongoing
2
222
Europe, RoW
Carfilzomib, pomalidomide, Dexamethasone, [NA], Solution for injection, Capsule, hard, Tablet, Imnovid 1 mg, Imnovid 2 mg, Imnovid 3 mg, Imnovid 4 mg
HOVON Foundation, Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon), HOVON, Dutch Cancer Society, Celgene International, Amgen Ltd, Dutch cancer society, Onyx Pharmaceuticals
Multiple Myeloma Multiple Myeloom, Multiple Myeloma Multiple Myeloom, ziekte van Kahler, Diseases [C] - Cancer [C04]
 
 
2013-005157-75: Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients

Ongoing
2
116
Europe, RoW
Kyprolis, Revlimid 5mg, Revlimid 10mg, Revlimid 15mg, Revlimid 25mg, N/A, Lyophilisate for solution for injection, Capsule, hard, Kyprolis, Revlimid 5mg, Revlimid 10mg, Revlimid 15mg, Revlimid 25mg
HOVON Foundation, HOVON, Dutch Cancer Society, Dutch Cance Society, HOVON
Primary plasma cell leukemia, Primary plasma cell leukemia, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02235740: A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Terminated
2
1
US
Afuresertib, Carfilzomib
Novartis, Amgen
Cancer
10/15
10/15
2009-014922-40: Carfilzomib in combination with Thalidomide and Dexamethasone for remission induction and consolidation of Multiple Myeloma at first presentation

Ongoing
2
50
Europe
CARFILZOMIB, PR-171,
Erasmus MC, Onyx pharmaceuticals
Multiple myeloma at first presentation Multipel myeloom
 
 
2012-001320-36: A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) compared to cyclophosphamide, velcade and dexamethasone (CVD)for first relapse or primary refractory mutiple myeloma patients.

Ongoing
2
300
Europe
Carfilzomib, Cyclophosphamide, Dexamethasone, Velcade, Dexamethasone, Velcade, Dexamethasone, Velcade
University of Leeds, Myeloma UK
multiple myeloma at the first relaspe of primary refractory disease stage
 
 
2012-005804-16: Front-line therapy with Carfilzomib, Lenalidomide, and Dexamethasone (CRd) induction followed by autologous stem cell transplantation, CRd consolidation and Lenalidomide maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 years old : a phase II study of the Intergroupe Francophone du Myélome (IFM) Traitement de première ligne par Carfilzomib, Lenalidomide et Dexamethasone (CRd) en induction suivi par une autogreffe de cellules souches, un traitement de consolidation par CRd et un entretien par Lenalidomide chez les patients de ≤65 ans atteints de Myélome Multiple de novo : une étude de phase II de l’Intergroupe Francophone du Myélome (IFM)

Ongoing
2
46
Europe
CARFILZOMIB, REVLIMID (LENALIDOMIDE) 25mg, CARFILZOMIB, REVLIMID (LENALIDOMIDE) 5mg, REVLIMID (LENALIDOMIDE) 25mg, CARFILZOMIB, REVLIMID (LENALIDOMIDE) 5mg
CHU de Toulouse, Onyx, Celgene
Multiple Myeloma Myelome Multiple
 
 
NCT02020941: Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy

Terminated
2
10
US
carfilzomib, Kyprolis, PR-171, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, laboratory biomarker analysis
Attaya Suvannasankha, National Cancer Institute (NCI)
Refractory Multiple Myeloma
01/16
04/16
NCT01351623: Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

Completed
2
44
US
Carfilzomib
Memorial Sloan Kettering Cancer Center, Amgen
Multiple Myeloma
01/16
01/16
NCT01989325: A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma

Checkmark For advanced MM of carfilzomib + filanesib combination at ASH 2015
Dec 2015 - Dec 2015: For advanced MM of carfilzomib + filanesib combination at ASH 2015
Completed
2
77
US
Carfilzomib, proteasome inhibitor; intravenous, Filanesib, KSP(Eg5) inhibitor; intravenous, Dexamethasone, steroid; oral or intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Pfizer
Advanced Multiple Myeloma
02/16
05/16
NCT01775553: Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib

Completed
2
13
US
Carfilzomib, High Dose Carfilzomib
Ajai Chari, Amgen
Relapse Multiple Myeloma, Refractory Multiple Myeloma
05/16
05/16
NCT01559935: Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

Active, not recruiting
2
74
US
carfilzomib, Dexamethasone, DECADRON®, Clarithromycin, Biaxin, Lenalidomide, Revlimid
Weill Medical College of Cornell University, Onyx Therapeutics, Inc.
Multiple Myeloma
06/16
03/25
NCT02092922 / 2014-001051-23: A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)

Hourglass May 2016 - May 2016 : AFFIRM trial
Completed
2
154
Europe, Canada, US
Filanesib, KSP (Eg5) inhibitor; intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Pfizer
Advanced Multiple Myeloma
07/16
09/17
NCT01402284 / 2007-001828-12: Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

Checkmark multiple myeloma
Nov 2013 - Nov 2013: multiple myeloma
Checkmark P2 data ASCO
Jun 2012 - Jun 2012: P2 data ASCO
Completed
2
45
US
Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone, Ozurdex
National Cancer Institute (NCI), Celgene, Onyx Therapeutics, Inc.
Multiple Myeloma
07/16
09/20
NCT01470196: Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia

Completed
2
31
US
Dexamethasone, Decadron, Carfilzomib, PR-171, Rituximab, Rituxan
Dana-Farber Cancer Institute, Amgen
Waldenstrom's Macroglobulinemia
09/16
09/16
FORTE, NCT02203643: Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

Active, not recruiting
2
477
Europe
Carfilzomib, Cyclophosphamide, Lenalidomide, Revlimid, Dexamethasone
Mario Boccadoro
MULTIPLE MYELOMA (MM)
10/16
10/33
NCT00884312: A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols

Completed
2
101
US, Canada
Carfilzomib, PR-171, PR171, Kyprolis®
Amgen
Multiple Myeloma, Solid Tumors
05/17
05/17
IFM-CRd, NCT02405364: Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction

Unknown status
2
46
Europe
Carfilzomib/Lenalidomide/Dexamethasone, New drug combination
University Hospital, Toulouse, Onyx Therapeutics, Inc., Celgene
Multiple Myeloma
06/17
12/20
SCORE, NCT02628704: Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma

Checkmark Data from SCORE study of selinexor in combination with carfilzomib [TRIAL WITHDRAWN]
Mar 2017 - Mar 2017: Data from SCORE study of selinexor in combination with carfilzomib [TRIAL WITHDRAWN]
Checkmark Interim data from SCORE trial in refractory multiple myeloma [TRIAL WITHDRAWN]
Mar 2017 - Mar 2017: Interim data from SCORE trial in refractory multiple myeloma [TRIAL WITHDRAWN]
Checkmark Initiation of P2/3 SCORE trial in refractory multiple myeloma [TRIAL WITHDRAWN]
More
Withdrawn
2
0
US
Selinexor, KCP-330, Placebo (for selinexor), carfilzomib, Kyprolis, Dexamethasone
Karyopharm Therapeutics Inc
Multiple Myeloma
06/17
06/18
NCT02047253: Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

Completed
2
28
US
Carfilzomib, Kyprolis, Dexamethasone, Acyclovir, Zovirax
University of Alabama at Birmingham, Amgen
Metastatic Castration-resistant Prostate Cancer
06/17
07/17
2016-003105-33: Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients Trattamento con carfilzomib e lenalidomide per i pazienti giovani e anziani affetti da leucemia plasmacellulare primaria alla diagnosi

Ongoing
2
116
Europe
Carfilzomib, REVLIMID, Revlimid, L01XX45, Solution for infusion, Capsule, hard, REVLIMID - 5 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CASPULE, REVLIMID - 10 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE, REVLIMID - 15 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE, REVLIMID - 25 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE
HOVON, Celgene International, Onyx Pharmaceuticals
Primary plasma cell leukemia Leucemia Plasma Cellulare, Primary plasma cell leukemia Leucemia Plasma Cellulare, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2017-000586-72: Kyprolis-Revlimid-dexamethasone consolidation treatment in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study

Ongoing
2
50
Europe
dexamethasone, Concentrate and solvent for concentrate for solution for infusion, Kyprolis
Oslo University Hospital, Nordic Myeloma Study Group (NMSG)
Multiple Myeloma, Multiple Myeloma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
SWOG-S1304, NCT01903811: S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

Completed
2
143
US
Carfilzomib, Kyprolis, PR-171, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Laboratory Biomarker Analysis
Southwest Oncology Group, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
11/17
03/19
NCT02042950: A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Terminated
2
6
US
Carfilzomib
M.D. Anderson Cancer Center, Onyx Therapeutics, Inc.
Lymphoma
12/17
12/17
2016-004778-16: Use of a novel chemotherapeutic regimen in an attempt to eradicate residual myeloma disease after a first autologous stem cell Transplantation. Einsatz einer neuen Kombinationschemotherapie mit dem Ziel, nach einer ersten autologen Stammzelltransplantation verbleibende Reste einer Myelomerkrankung zu eradizieren.

Ongoing
2
41
Europe
Lenalidomide, Fortecortin, CC-5013, -, Powder for solution for infusion, Capsule, hard, Tablet, Kyprolis, REVLIMID 25 mg, Fortecortin
Department of Medicine I, Ordensklinikum Linz, Elisabethinen Hospital Linz, Amgen (Europe) GmbH
Multiple Myeloma Multiples Myelom, A special type of bone marrow cancer Eine Form des Knochenmarkskrebses, Diseases [C] - Cancer [C04]
 
 
NCT02491359: Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

Completed
2
20
US
Carfilzomib, Kyprolis, PR-171, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Chronic Graft Versus Host Disease
02/18
09/18
NCT01816971: Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Checkmark EHA 2014
May 2014 - May 2014: EHA 2014
Active, not recruiting
2
76
Canada, US
dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, carfilzomib, Kyprolis, PR-171, lenalidomide, CC-5013, IMiD-1, Revlimid, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis
University of Chicago, National Cancer Institute (NCI)
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
04/18
12/26
ACTRN12615000934549: A multicentre single arm study of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (MM) patients refractory to initial bortezomib-based induction therapy

Active, not recruiting
2
50
 
Australiasian Leukaemia and Lymphoma Group, Onyx Pharmaceuticals Inc., a subsidiary of Amgen, Inc.
Multiple Myeloma
 
 
CARFI, NCT02572492 / 2013-003789-15: Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support

Unknown status
2
200
Europe
Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan, Kyprolis, Carfilzomib/dexamethasone maintenance, Observation without carfilzomib/dexamethasone maintenance
Henrik Gregersen, Nordic Myeloma Study Group
Multiple Myeloma
04/18
04/19
GEM-CESAR, NCT02415413 / 2014-002948-40: Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Active, not recruiting
2
90
Europe
carfilzomib, Lenalidomide, Dexamethasone, Melphalan
PETHEMA Foundation, Celgene Corporation, Amgen
Smoldering Multiple Myeloma
07/18
06/27
NCT02114502: Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Withdrawn
2
0
US
Carfilzomib, SAHA, Vorinostat, Suberoylanilide Hydroxamic Acid, MSK-390, Zolinza, Gemcitabine, Gemcitabine Hydrochloride, Gemzar, Busulfan, Busulfex, Myleran, Melphalan, Alkeran, Stem Cell Transplant (SCT), Palifermin, Kepivance, Dexamethasone, Decadron, Caphosol, Glutamine, Enterex, Glutapak-10, NutreStore, Resource, GlutaSolve, Sympt-X G.I., Sympt-X, Pyridoxine
M.D. Anderson Cancer Center
Myeloma
09/18
 
NCT03269552: Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

Terminated
2
4
US
Carfilzomib, Kyprolis, PR-171, Laboratory Biomarker Analysis, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83
University of Washington, National Cancer Institute (NCI)
Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia
12/18
12/18
NCT01775930: Carfilzomib in Refractory Renal Cell Carcinoma (RCC)

Completed
2
10
US
Carfilzomib
M.D. Anderson Cancer Center, Onyx Therapeutics, Inc.
Kidney Cancer
01/19
01/19
NCT02128230: UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Terminated
2
20
US
myPRS, Gep70, Induction 1 - MEL-10+CFZ-TD-PACE, Melphalan (Alkeran™), Carfilzomib (Kyprolis®), Thalidomide (Thalomid®), Dexamethasone (Decadron®), Cisplatin (CDDP) (Platinol®), Doxorubicin (Adriamycin®), Cyclophosphamide (Cytoxan®), Etoposide (VP-16) (Vepesid®), Granulocyte colony-stimulating factor (G-CSF), filgrastim (Neupogen®), First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Autologous Peripheral Blood Stem Cell Transplant, Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D, Lenalidomide (CC-5013) (Revlimid®)
University of Arkansas, Amgen
Multiple Myeloma
02/19
02/19
NCT03140943: Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Unknown status
2
100
RoW
Carfilzomib, Thalidomide and Dexamethasone
National University Hospital, Singapore, The Australasian Leukaemia & Lymphoma Group (ALLG), International Myeloma Foundation, Celgene
Relapsed and/or Refractory Multiple Myeloma
06/19
06/22
NCT02597062: High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Completed
2
76
Canada
Carfilzomib, Cyclophosphamide, Dexamethasone
Canadian Cancer Trials Group, Amgen, Canadian Myeloma Research Group
Multiple Myeloma
06/19
02/22
2018-000540-25: Carfilzomib + Lenalidomide +Dexamethasone for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas Terapia di salvataggio ( Carfilzomib + Lenalidomide +Desametasone) per linfomi mantellari ricaduti, refrattari o intolleranti a trattamento con inibitori di BTK

Not yet recruiting
2
59
Europe
REVLIMID/LENALIDOMIDE, KRYPOLIS, [IMP1 - 5 MG], [IMP2], [IMP3- 10 MG], [IMP4 - 25 MG], Capsule, hard, Powder for solution for infusion, REVLIMID, KYPROLIS, REVLIMID - 15 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE
FONDAZIONE ITALIANA LINFOMI ONLUS, CELGENE, AMGEN
BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas Linfomi mantellari ricaduti, refrattari o intolleranti a trattamento con inibitori di BTK, BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas Linfomi mantellari ricaduti, refrattari o intolleranti a trattamento con inibitori di BTK, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
AMN004, NCT03143036: Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

Unknown status
2
100
RoW
Daratumumab, thalidomide and dexamethasone
National University Hospital, Singapore, Janssen, LP, International Myeloma Foundation
Relapse and / or Refractory Myeloma
07/19
07/22
2019-001027-12: Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma

Not yet recruiting
2
90
Europe
Pomalidomide, Carfilzomib, Isatuximab, Pomalidomide, Carfilzomib, Isatuximab, Capsule, Powder for solution for infusion, Solution for injection, Pomalidomide, Carfilzomib, Isatuximab
CHU de Poitiers, CHU de Poitiers
Multiple myeloma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03104270: Combination Study for High Risk Multiple Myeloma Patients

Terminated
2
13
US
Elotuzumab, BMS-901608, Pomalidomide, CC-4047, Pomalyst, Carfilzomib, Kyprolis, Dexamethasone, Steroid
Oncotherapeutics
Multiple Myeloma
10/19
01/20
Cardamon, NCT02315716 / 2014-000506-35: Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Multiple Myeloma

Active, not recruiting
2
281
Europe
Autologous Stem Cell Transplant (ASCT), Consolidation with 4 cycles of CarCyDex
University College, London, Amgen
Multiple Myeloma
11/19
11/29
NCT03512353: A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

Terminated
2
7
US
Dexamethasone, Carfilzomib, Kyprolis®
Amgen
Relapsed or Refractory Multiple Myeloma
01/20
01/20
ACTRN12614000301662: Phase II study assessing the effect of carfilzomib treatment on early free light chain kinetics in myeloma patients with renal impairment

Completed
2
40
 
Australiasian Leukemia and Lymphoma Group, Amgen (Europe) GmbH
Multiple Myeloma with Renal Impairment
 
 
2019-001645-41: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study

Not yet recruiting
2
462
Europe
Darzalex, Bortezomib, Dexamethasone, HUMaX-CD38, L01XX32, Dexamethasone, Capsule, hard, Powder for solution for infusion, Concentrate for solution for infusion, Powder for solution for injection, Tablet, Revlimid, Kyprolis, Darzalex, Velcade, Dexamethasone
Memorial Sloan Kettering Cancer center, Amgen
Newly diagnosed Multiple Myeloma Multipelt Myelom, Multiple Myeloma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
ACTRN12615000818538: Single arm, multicentre study of Carfilzomib in combination with Thalidomide and Dexamethasone (CaTD) in patients with relapsed and/or refractory multiple myeloma (RRMM).

Completed
2
100
 
Australiasian Leukaemia and Lymphoma Group, Australasian Leukaemia and Lymphoma Group
Multiple Myeloma
 
 
NCT03805178: Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization

Withdrawn
2
0
NA
Belatacept, Nulojix, Carfilzomib, Kyprolis
Duke University, Bristol-Myers Squibb
Lung Transplant Rejection, Antibody-mediated Rejection
08/20
10/20
NCT03412565: A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Checkmark Data from PLEIADES study for 1L newly diagnosed or rel/ref multiple myeloma at IMW 2019
Sep 2019 - Sep 2019: Data from PLEIADES study for 1L newly diagnosed or rel/ref multiple myeloma at IMW 2019
Checkmark Data from PLEIADES trial in multiple myeloma at IMW 2019
Aug 2019 - Aug 2019: Data from PLEIADES trial in multiple myeloma at IMW 2019
Completed
2
265
Europe, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Melphalan, Prednisone, Carfilzomib
Janssen Research & Development, LLC
Multiple Myeloma
08/20
04/24
NCT02294357: Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Terminated
2
45
US
Carfilzomib, Kyprolis, Dexamethasone, Decadron, Dexamethasone acetate, Prednisone, Deltasone, Cortan, Methylprednisolone, Medrol, Methylprednisolone acetate, Lenalidomide, Revlimid, Pomalidomide, Pomalyst
Oncotherapeutics, Amgen
Multiple Myeloma
09/20
09/20
NCT02217163: Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma

Completed
2
30
RoW
Carfilzomib, , Cyclophosphamide, Dexamethasone, Kyprolis
Singapore General Hospital
Multiple Myeloma
10/20
10/20
ACTRN12615000188538: KIWI Study- Kyprolis based Induction in untreated Myeloma with Kyprolis post Transplant Consolidation

Active, not recruiting
2
50
 
North Shore Haematology Clinical Trial Unit, Amgen Inc
Multiple Myeloma
 
 
NCT02188368: Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Terminated
2
45
US
POM, Pomalidomide, Pomalyst, Actimid, CC-4047, Steroids, Dexamethasone, prednisone, methyprednisolone, PLD, Pegylated liposomal doxirrubicin, CFZ, Carfilzomib, Kyprolis, BTZ, Bortezomib, Velcade, CLA, Clarithromycin, CY, Cyclophosphamide
Oncotherapeutics, Celgene Corporation
Multiple Myeloma
10/20
10/20
NCT02474927: Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation

Completed
2
22
US
Carfilzomib, Kyprolis
John F. McDyer, MD
Lung Transplant Rejection
11/20
07/21
FIL_KLIMT, NCT03891355: Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

Active, not recruiting
2
16
Europe
Carfilzomib, Lenalidomide, Dexamethasone
Fondazione Italiana Linfomi ONLUS
Mantle Cell Lymphoma
12/20
12/22
PANORAMA-5, NCT02756663: Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Withdrawn
2
0
US, Canada, Europe, RoW
panobinostat (capsules), PAN, LBH589, carfilzomib (infusion), CFZ, dexamethasone (tablets), Dex
Novartis Pharmaceuticals
Multiple Myeloma
02/21
02/21
NCT03256045: Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Terminated
2
9
US
Carfilzomib, Kyprolis, PR-171, Chemosensitivity Assay, Chemosensitivity Testing, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Laboratory Biomarker Analysis, Panobinostat, Faridak, Farydak, LBH589
University of Washington, National Cancer Institute (NCI), SecuraBio
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
02/21
02/21
2020-003092-18: Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma inducedacute renal failure requiring dialysis - “Time Is Kidney in the Treatment of myelomA Cast nephropathy”

Ongoing
2
50
Europe
Solution for injection, Powder for solution for infusion, Capsule, hard, Tablet, DARZALEX, Kyprolis, Imnovid, Fortecortin
Medical University Innsbruck, AMGEN GmbH, Calgene GmbH, Janssen GmbH
Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Up to 40% of the myeloma patients present with renal failure at diagnosis and approximately 10% require dialysis., Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Up to 40% of the myeloma patients present with renal failure at diagnosis and app. 10% require dialysis., Diseases [C] - Cancer [C04]
 
 
NCT02318784: Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Completed
2
62
US
Carfilzomib, Kyprolis
SCRI Development Innovations, LLC, Amgen
Neuroendocrine Cancer
05/21
05/21
Elo-KRd, NCT03361306: LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

Active, not recruiting
2
15
US
Elotuzumab, Empliciti
Wake Forest University Health Sciences, Bristol-Myers Squibb, Atrium Health Levine Cancer Institute
Multiple Myeloma
06/21
02/25
IFM2012-03, NCT02302495 / 2012-004490-10: Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma

Unknown status
2
80
Europe
Carfilzomib, Melphalan, Prednisone
University Hospital, Lille, Amgen
Multiple Myeloma
07/21
07/21
KyDaR, NCT04065789: Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients

Completed
2
41
RoW
Carfilzomib, Kyprolis, Daratumumab, Darzalex, Lenalidomide, Revlimid, Dexamethasone
Tel-Aviv Sourasky Medical Center
Myeloma Multiple, Myeloma, Plasma-Cell, Myeloma-Multiple, Plasma Cell Myeloma
08/21
11/21
CONPET, NCT03314636: Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.

Active, not recruiting
2
53
Europe
Carfilzomib, Lenalidomide, PET-CT, Dexamethasone
Oslo University Hospital, Nordic Myeloma Study Group
Myeloma
11/21
11/26
2021-001798-21: A Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Not yet recruiting
2
153
RoW
Magrolimab, Daratumumab, Dexamethasone, Pomalidomide, Bortezomib, carfilzomib, GS-4721, Concentrate for solution for infusion, Solution for infusion, Tablet, Capsule, hard, Powder for solution for injection, Powder for solution for infusion, Solution for injection
Gilead Sciences, Inc., Gilead Sciences, Inc.
Relapsed/Refractory Multiple Myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
IFM 2018-04, NCT03606577: An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

Active, not recruiting
2
50
Europe
Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone
Nantes University Hospital
Multiple Myeloma
02/22
11/27
12-C-0107, NCT01572480: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

Active, not recruiting
2
55
US
Carfilzomib, Kyprolis, Revlimid, Lenalidomide, Dexamethasone, Ozurdex
National Cancer Institute (NCI)
Multiple Myeloma
03/22
06/28
DART4MM, NCT03992170: Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive

Recruiting
2
50
Europe
Daratumumab, Darzalex
Azienda Ospedaliera Universitaria Senese, Janssen-Cilag S.p.A.
Myeloma Multiple
06/22
12/22
SKylaRk, NCT04430894: KRDI in Transplant-Eligible MM

Active, not recruiting
2
50
US
Carfilzomib, Kyprolis, Isatuximab, Sarclisa, Lenalidomide, REVLIMID, Dexamethasone, Decadron
Massachusetts General Hospital, Amgen, Sanofi
Multiple Myeloma
07/22
03/25
NCT03871829 / 2018-004185-34: Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Terminated
2
88
Europe, Canada, US, RoW
Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2, Dexamethasone 40 mg, Dara-SC 1800 mg, Dexamethasone 20 mg
Janssen Research & Development, LLC
Multiple Myeloma
10/22
01/23
NCT04191616 / 2019-001169-34: Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Active, not recruiting
2
54
Europe, US
Carfilzomib, Kyprolis, Dexamethasone, Decadron, Ozurdex, DexPak 6, 10, 13 Day, ReadySHarp, LoCort, Maxidex, Pomalidomide, Pomalyst
Amgen
Relapsed or Refractory Multiple Myeloma
11/22
10/24
2022-001418-20: A Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma Estudio para evaluar la seguridad y la tolerabilidad de modakafusp alfa intravenoso como parte de un tratamiento combinado en pacientes adultos con mieloma múltiple

Not yet recruiting
2
144
Europe
Modakafusp Alfa, Darzalex, TAK-573, Powder for concentrate for solution for infusion, Capsule, hard, Solution for injection, Powder for solution for infusion, Zelvina 5 mg Hard Capsules, Zelvina 10 mg Hard Capsules, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Bortezomib STADA 2.5 mg/ml solution for injection, Kyprolis 30 mg powder for solution for infusion, Darzalex 1800mg solution for injection
Takeda Development Center Americas, Inc., Takeda Development Center Americas, Inc.
Multiple Myeloma Mieloma múltiple, Multiple Myeloma Mieloma múltiple, Diseases [C] - Cancer [C04]
 
 
2022-002767-30: A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma

Not yet recruiting
2
75
RoW, Europe
isatuximab, carfilzomib, dexamethasone, SAR650984, Solution for injection, Powder for solution for infusion, Tablet, Kyprolis® 60 mg, DexaGalen®, Dexamethason 4 mg JENAPHARM®
Sanofi-aventis recherche & developpement, Sanofi-aventis recherche & developpement
Relapsed/refractory multiple myeloma (RRMM), Multiple myeloma, Diseases [C] - Cancer [C04]
 
 
2022-004207-32: Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure NOT requiring dialysis

Not yet recruiting
2
50
Europe
Darzalex, Kyprolis, Imnovid, Fortecortin, Concentrate for solution for infusion, Powder for solution for infusion, Capsule, hard, Tablet, DARZALEX, Kyprolis, Imnovid, Fortecortin
Medical University Innsbruck, Internal Medicine V, AMGEN GmbH, Calgene GmbH, Janssen GmbH
Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Patients with renal failure have a poor prognosis., Multiple Myeloma: Patients with MM are frequently diagnosed primarily due to renal failure. Patients with renal failure have a poor prognosis., Diseases [C] - Cancer [C04]
 
 
MASTER, NCT03224507: Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma

Completed
2
123
US
KRdD followed by auto-HCT, KRdD = Kyprolis (Carfilzomib), Revlimid (Lenalidomide), dexamethasone, Darzalex (Daratumumab), KRdD only
University of Alabama at Birmingham, Amgen, Janssen Scientific Affairs, LLC
Multiple Myeloma
05/23
06/23
NCT04113018: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Active, not recruiting
2
39
US
Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
Wake Forest University Health Sciences, Amgen, Celgene, Janssen, LP
Multiple Myeloma
06/23
10/27
NCT03155100 / 2016-001178-13: Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines

Completed
2
15
Europe
Carfilzomib for Inj 60 milligram (MG), Proteasome inhibitor, Elotuzumab 400 MG, Monoclonal antibody, Dexamethasone, Steroid
Raija Silvennoinen, Amgen, Bristol-Myers Squibb, Hospital District of Helsinki and Uusimaa
Multiple Myeloma in Relapse
08/23
08/23
NCT03004287: 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active, not recruiting
2
50
US
Carfilzomib, Kyprolis, Thalidomide, Thalomid, Dexamethasone, Baycadron, Daratumumab, Darzalex, Cisplatin, Platinol, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan, Etoposide, Eposin, Melphalan, ASCT, Lenalidomide, Revlimid, Bortezomib, Velcade
University of Arkansas, Janssen, LP
Multiple Myeloma
10/24
10/25
NCT06140966: Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Recruiting
2
54
RoW
Daratumumab, Darzalex, Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone, Baycadron, Cisplatin, Platinol, epirubicin, Pharmorubicin, Cyclophosphamide, Cytoxan, Etoposide, Eposin, Melphalan, Alkeran, ASCT, autologous stem cell transplantation, bortezomib, Velcade
Wuhan Union Hospital, China
Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma
10/26
10/27
NCT04392037: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone

Active, not recruiting
2
60
Europe
Iberdomide plus low-dose cyclophosphamide and dexamethasone, CC-220
Amsterdam UMC, location VUmc, Celgene
Multiple Myeloma
12/24
12/24
ASCENT, NCT03289299: Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Active, not recruiting
2
87
US
Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone
International Myeloma Foundation, Amgen, Janssen Scientific Affairs, LLC, Celgene, Trevie, Inc.
Smoldering Multiple Myeloma
09/23
11/31
iStopMM, NCT03815279 / 2017-004785-10: A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)

Enrolling by invitation
2
80
RoW
Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone, Dexasone
Landspitali University Hospital, Amgen, Celgene, University of Iceland, Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Smoldering Multiple Myeloma
01/24
01/28
NCT04661137: A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Recruiting
2
96
US
Selinexor 60 MG, KPT-330, Selinexor 80 MG, Selinexor 100 MG, Carfilzomib, Kyprolis, Pomalidomide, Pomalyst, Daratumumab, Darzalex, Dexamethasone, Dextenza, Ozurdex, Neofordex, others
Hackensack Meridian Health, Karyopharm Therapeutics Inc
Multiple Myeloma
01/25
01/25
AGMT-MM02, NCT02891811 / 2016-000475-24: Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy

Completed
2
124
Europe
Carfilzomib, Kyprolis, Thalidomide, Lenalidomide, Dexamethasone
Arbeitsgemeinschaft medikamentoese Tumortherapie, Amgen
Multiple Myeloma
03/24
03/24
NCT04176718: Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Recruiting
2
43
US
Daratumumab, Darzalex, Carfilzomib, Kyprolis, Pomalidomide, Pomalyst, Imnovid, Dexamethasone, Dexasone, Diodex, hexadrol
Andrew Yee, MD, Amgen, Janssen Research & Development, LLC
Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
05/25
05/26
KMM1911, NCT05497102: Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT

Recruiting
2
58
RoW
Lenalidomide maintenance
Samsung Medical Center
Multiple Myeloma
05/24
12/25
SubQSA, NCT06356571: A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Not yet recruiting
2
64
NA
Isatuximab SC-OBDS, SAR650984, Sarclisa, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib
Sanofi
Plasma Cell Myeloma Refractory
01/27
07/27
NCT05704049: A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting
2
71
Europe, Japan, RoW
Isatuximab, Carfilzomib, Kyprolis, Dexamethasone, Dexamethasone IV, Montelukast, Acetaminophen, Diphenhydramine, Methylprednisolone
Sanofi
Relapsed/Refractory Multiple Myeloma
10/24
03/27
KMM2002, NCT05509374: Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone

Recruiting
2
33
RoW
Carfilzomib 56 MG [Kyprolis], Pomalidomide, Dexamethasone
Samsung Medical Center
Multiple Myeloma
06/24
06/24
NCT03556332: A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Active, not recruiting
2
41
US
Carfilzomib, Lenalidomide, Dexamethasone, Daratumumab, autologous hematopoietic cell transplantation
Memorial Sloan Kettering Cancer Center, Janssen Pharmaceuticals
Multiple Myeloma
07/25
07/25
DARALLO, NCT04024384: Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial

Withdrawn
2
0
Europe
Daratumumab
Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
07/24
07/24
NCT03756896: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma

Active, not recruiting
2
29
US
Carfilzomib, Kyprolis, PR-171, Dexamethasone, Decadron, Dekacort, Dexameth, Hexadrol, Pomalidomide, 4-Aminothalidomide, Actimid, CC-4047, Imnovid, Pomalyst
Emory University, Amgen, National Cancer Institute (NCI), National Institutes of Health (NIH)
Plasma Cell Myeloma
03/25
03/26
HO147SMM, NCT03673826 / 2017-000555-10: Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM

Active, not recruiting
2
58
Europe, RoW
Carfilzomib, Dexamethasone, Lenalidomide
Stichting Hemato-Oncologie voor Volwassenen Nederland
Smouldering Myeloma
08/24
12/28
NCT03290950: A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting
2
75
US
daratumumab, carfilzomib, lenalidomide, dexamethasone, Cohort 1 administration, Cohort 2 administration
Memorial Sloan Kettering Cancer Center, Janssen Pharmaceuticals
Multiple Myeloma
09/24
09/24
 

Download Options